DUBLIN, Ireland , June 01, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive ...
Reported positive topline data from the pivotal Phase 3 REST-ON study Strengthened balance sheet with $190 million in gross proceeds from a private placement in February 2020 and public equity offering in May 2020 Reported ...
We are a global pharmaceutical company, proud to be unique in our space as experts in the development and commercialization of safe, novel products that address unmet medical needs through improved dosing and by ensuring the safety and efficacy of our products and product candidates.
Whether we are seeking FDA approval of commonly used drugs, acquiring new assets or utilizing our innovative technologies to change the method of administering medication, Avadel approaches every product with the patient in mind.